Sivia Capital Partners LLC Sells 121 Shares of Eli Lilly and Company $LLY

by · The Cerbat Gem

Sivia Capital Partners LLC lessened its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,971 shares of the company’s stock after selling 121 shares during the quarter. Eli Lilly and Company accounts for approximately 0.5% of Sivia Capital Partners LLC’s portfolio, making the stock its 23rd largest holding. Sivia Capital Partners LLC’s holdings in Eli Lilly and Company were worth $1,537,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in LLY. PNC Financial Services Group Inc. increased its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC increased its stake in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Nuveen LLC bought a new position in Eli Lilly and Company in the first quarter valued at $4,613,912,000. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the last quarter. Finally, Cohen Investment Advisors LLC increased its stake in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after acquiring an additional 773,947 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Guggenheim reduced their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $939.61.

Read Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Stock Performance

Shares of LLY opened at $760.39 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.86. The company has a 50-day simple moving average of $739.72 and a two-hundred day simple moving average of $774.13. The firm has a market capitalization of $719.68 billion, a PE ratio of 49.70, a price-to-earnings-growth ratio of 1.06 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business posted $3.92 earnings per share. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 39.22%.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories